The recently developed FXR agonist (Obeticholic acid) has been demonstrated to improve the ALP level in primary biliary cirrhosis [102], and has also been investigated for the treatment of nonalcoholic steatohepatitis (NASH) [103–105]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.